← Back to all trials
Active Not Recruiting
NCT06510816
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Conditions: Geographic Atrophy
Sex: All
Ages: 50 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 659
Sponsor: Annexon, Inc.
Location: Retina Macula Institute of Arizona Scottsdale Arizona
Summary
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.
Exclusion Criteria:
* Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.
NOTE: Other protocol-defined inclusion and exclusion criteria apply.
Source: ClinicalTrials.gov (NCT06510816). StuddyBuddy aggregates publicly available trial information.
